This trial is active, not recruiting.

Condition genital human papilloma virus infection
Treatments topical application cervical spray, topical spray on the cervix, cervical swab with cervex-brush-combi at t0, cervical swab with cervex-brush-combi at t1
Phase phase 2
Sponsor Cesa Projects International
Start date August 2012
End date December 2012
Trial size 100 participants
Trial identifier NCT01654822, AV2-HPV-001


This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.

- Primary endpoint: significant drop in viral load AV2-DM versus placebo

- Secondary endpoint:the number of patients with adverse events

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Placebo Comparator)
Topical spray one-time administration 2 puffs of 100µl
topical spray on the cervix
one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
cervical swab with cervex-brush-combi at t0
cervical swab with cervex-brush-combi at t1
Topical spray one-time application 2 puffs of 100µl
topical application cervical spray
one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
cervical swab with cervex-brush-combi at t0
cervical swab with cervex-brush-combi at t1

Primary Outcomes

Efficacy comparison number of patients with drop (min 2 Log units) in HPV specific viral load AV2-DM versus placebo
time frame: 90 days

Secondary Outcomes

number of adverse vents AV2-DM versus placebo
time frame: 90 days

Eligibility Criteria

Female participants from 25 years up to 40 years old.

Inclusion Criteria: 1. Women between 25 and 40 years 2. Patient has been recently (up to 6 months) Quantitatively (Viral Load) and Qualitatively (HPV types) diagnosed with HPV. 3. Ability and willingness to participate in the study. 4. Subject agrees to refrain from using prescription or supplemental antiviral medications without obtaining permission of the Treating Doctor. 5. Voluntary written informed consent. Exclusion Criteria: 1. Subject has been vaccinated against HPV 2. Interval between a delivery and T0 is less than 3 months 3. Subject has a gynecologic surgical intervention between T0 and T1 4. Subject is diagnosed HPV negative at T0 5. Subject has a (adeno)carcinoma in situ. 6. Females with child bearing potential who are not using a reliable, medically accepted method of birth control 7. Pregnant or breast-feeding female, or women planning to become pregnant during the trial. 8. Medical history of immunosuppression by radiotherapy, chemotherapy, immuno-modulatory drugs, or HIV. 9. Participation to another clinical trial concerning HPV infections within 6 months before the application of AV2-DM antiviral spray. 10. Medical history of any severe diseases like hepatitis, renal or liver dysfunction, car-diovascular, gastrointestinal, malignant tumor(s), or psychiatric disorders etc., which might influence the assessments or conduct of the trial by the discretion of the investigator. 11. Intake or application of antivirals or other prohibited concomitant medication within 30 days prior to application of AV2, or patients who plan to take such drugs during the trial. 12. Known or suspected allergic or adverse response to the investigational product AV2-DM Antiviral spray, it's components, olive oil or d-limonene. 13. Inability to follow the study protocol.

Additional Information

Official title Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load
Trial information was received from ClinicalTrials.gov and was last updated in November 2012.
Information provided to ClinicalTrials.gov by Cesa Projects International.